Skip to main content
. 2021 Aug 22;22(11):e13326. doi: 10.1111/obr.13326

FIGURE 1.

FIGURE 1

Study selection. aStudies including liraglutide not used at 3.0 mg dose for weight loss. bStudies included the following non‐specified AOMs: PHEN/FEN, PHEN/FLU, mazindol, and caffeine/ephedrine, and a study that pooled 15 AOMs of which only five were eligible for this review. AOM, anti‐obesity medication; CEA, cost‐effectiveness analysis; FEN, fenfluramine; FLU, flunarizine; PHEN, phentermine; RWE, real‐world evidence